TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through the Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It off… Read more
TTY Biopharm Co Ltd (4105) - Net Assets
Latest net assets as of June 2025: NT$6.93 Billion TWD
Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has net assets worth NT$6.93 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$10.67 Billion) and total liabilities (NT$3.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$6.93 Billion |
| % of Total Assets | 64.91% |
| Annual Growth Rate | 2.99% |
| 5-Year Change | 23.57% |
| 10-Year Change | N/A |
| Growth Volatility | 6.68 |
TTY Biopharm Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how TTY Biopharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TTY Biopharm Co Ltd (2017–2024)
The table below shows the annual net assets of TTY Biopharm Co Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$7.51 Billion | +15.44% |
| 2023-12-31 | NT$6.51 Billion | +4.38% |
| 2022-12-31 | NT$6.23 Billion | +8.08% |
| 2021-12-31 | NT$5.77 Billion | -5.11% |
| 2020-12-31 | NT$6.08 Billion | -1.48% |
| 2019-12-31 | NT$6.17 Billion | -3.48% |
| 2018-12-31 | NT$6.39 Billion | +4.58% |
| 2017-12-31 | NT$6.11 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to TTY Biopharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$2.19 Billion | 32.45% |
| Other Components | NT$4.56 Billion | 67.55% |
| Total Equity | NT$6.75 Billion | 100.00% |
TTY Biopharm Co Ltd Competitors by Market Cap
The table below lists competitors of TTY Biopharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Head Co Ltd
SHE:002810
|
$486.91 Million |
|
Keshun Waterproof Technologies Co Ltd Class A
SHE:300737
|
$486.96 Million |
|
Zhuzhou Tianqiao Crane Co Ltd
SHE:002523
|
$486.98 Million |
|
Carabao Group Public Company Limited
BK:CBG-R
|
$487.33 Million |
|
ITOCHU ENEX
F:96P
|
$486.72 Million |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
$486.60 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
$486.53 Million |
|
Hagerty Inc
NYSE:HGTY
|
$486.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TTY Biopharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,941,340,000 to 6,750,448,000, a change of 809,108,000 (13.6%).
- Net income of 1,449,622,000 contributed positively to equity growth.
- Dividend payments of 870,275,000 reduced retained earnings.
- Other factors increased equity by 229,761,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.45 Billion | +21.47% |
| Dividends Paid | NT$870.27 Million | -12.89% |
| Other Changes | NT$229.76 Million | +3.4% |
| Total Change | NT$- | 13.62% |
Book Value vs Market Value Analysis
This analysis compares TTY Biopharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.66x to 2.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$22.11 | NT$80.90 | x |
| 2018-12-31 | NT$23.34 | NT$80.90 | x |
| 2019-12-31 | NT$22.40 | NT$80.90 | x |
| 2020-12-31 | NT$21.88 | NT$80.90 | x |
| 2021-12-31 | NT$20.75 | NT$80.90 | x |
| 2022-12-31 | NT$22.72 | NT$80.90 | x |
| 2023-12-31 | NT$23.85 | NT$80.90 | x |
| 2024-12-31 | NT$27.15 | NT$80.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TTY Biopharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.47%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.60%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.61x
- Recent ROE (21.47%) is above the historical average (19.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 24.46% | 32.97% | 0.43x | 1.73x | NT$795.05 Million |
| 2018 | 25.18% | 36.21% | 0.45x | 1.56x | NT$880.98 Million |
| 2019 | 16.16% | 20.15% | 0.47x | 1.71x | NT$343.02 Million |
| 2020 | 16.96% | 21.89% | 0.45x | 1.72x | NT$379.20 Million |
| 2021 | 16.10% | 18.34% | 0.49x | 1.80x | NT$315.11 Million |
| 2022 | 19.34% | 21.62% | 0.53x | 1.70x | NT$528.55 Million |
| 2023 | 18.99% | 20.50% | 0.56x | 1.66x | NT$534.38 Million |
| 2024 | 21.47% | 24.60% | 0.54x | 1.61x | NT$774.58 Million |
Industry Comparison
This section compares TTY Biopharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,352,544,333
- Average return on equity (ROE) among peers: 1.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TTY Biopharm Co Ltd (4105) | NT$6.93 Billion | 24.46% | 0.54x | $486.74 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |